Imugene’s Leslie Chong discusses with Proactive the news it’s received US Food and Drug Administration Investigational New Drug approval to initiate a phase I clinical trial of its oncolytic virotherapy candidate VAXINIA. Also this morning the company’s received US Food and Drug Administration Investigational New Drug approval to initiate a new phase 2 clinical trial of its immunotherapy candidate HER-Vaxx.
source
